Skip to main content
Year archive

Inventiva — 2023 filings

All 65 regulatory filings released by Inventiva (IVA) in 2023, sourced directly from the official regulator.

65 Filings
2023 Period
2023 filings (65)
Filing Released Lang
Inventiva annonce la randomisation du premier patient en Chine dans l’étude clinique NATiV3 et fait le point sur son programme de développement clinique
Regulatory Filings
2023-12-20 French
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
Regulatory Filings
2023-12-20 English
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
Regulatory Filings
2023-12-04 English
Inventiva annonce la recommandation positive du troisième DMC de l’étude clinique de Phase III avec lanifibranor dans la NASH
Regulatory Filings
2023-12-04 French
Inventiva reports 2023 Third Quarter Financial Information¹
Earnings Release 9M 2023
2023-11-21 English
Inventiva publie ses informations financières du 3ème trimestre 2023¹
Earnings Release 9M 2023
2023-11-21 French
Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
Regulatory Filings
2023-11-06 English
Inventiva annonce un abstract « late breaker » et deux abstracts supplémentaires sur son médicament candidat principal, lanifibranor, lors du Liver Meeting™ 2023 organisé par l’AASLD
Regulatory Filings
2023-11-06 French
Inventiva publie ses résultats financiers du 1er semestre 2023 et fait un point sur ses activités
Interim / Quarterly Report H1 2023
2023-09-28 French
Inventiva reports its 2023 first-half financial results and provides a corporate update
Earnings Release H1 2023
2023-09-28 English
RFS 30 juin 2023
Interim / Quarterly Report H2 2023
2023-09-28 French
Franchissement de seuils
Major Shareholding Notification
2023-09-28 French
Inventiva et Hepalys Pharma, Inc., signent un accord de licence exclusif pour développer et commercialiser lanifibranor au Japon et en Corée du Sud
Regulatory Filings
2023-09-20 French
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
Earnings Release FY 2023
2023-09-20 English
Franchissement de seuils
Major Shareholding Notification
2023-09-07 French
Franchissements de seuils
Major Shareholding Notification
2023-09-07 French
Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certifica
Share Issue/Capital Change
2023-08-31 English
Inventiva annonce un financement d'environ 35,7 millions d'euros auprès d'investisseurs nouveaux et existants, constitué d'une augmentation de capital réservée de 30,6 millions d'euros et d'une émissi
Capital/Financing Update
2023-08-31 French
Correction: Inventiva publie ses informations financières préliminaires du 1er semestre 2023¹ et fait un point sur ses activités
Earnings Release H1 2023
2023-07-27 French
Inventiva publie ses informations financières préliminaires du 1er semestre 2023¹ et fait un point sur ses activités
Earnings Release H1 2023
2023-07-27 French
Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update
Earnings Release H2 2023
2023-07-27 English
Inventiva annonce la présentation d’un abstract scientifique lors de la 82nd Scientific Sessions of the American Diabetes Association
Environmental & Social Information
2023-06-24 French
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
Regulatory Filings
2023-06-24 English
Inventiva annonce les résultats positifs de l’étude clinique initiée par un investigateur évaluant lanifibranor chez des patients atteints de DT2 et NAFLD
Earnings Release FY 2023
2023-06-13 French
Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD
Earnings Release FY 2022
2023-06-13 English
Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients
Regulatory Filings
2023-06-08 English
Inventiva et Echosens lancent une initiative conjointe pour mieux sensibiliser l’opinion à la NASH et faciliter l’accès au dépistage pour les patients à risque
Regulatory Filings
2023-06-08 French
Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023
Regulatory Filings
2023-06-07 English
Inventiva annonce cinq présentations scientifiques lors de l’EASL International Liver Congress™ 2023
Environmental & Social Information
2023-06-07 French
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunie le 25 mai 2023
Declaration of Voting Results & Voting Rights Announcements
2023-05-26 French
Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-05-26 English
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China
Regulatory Filings
2023-05-25 English
Inventiva annonce que son partenaire Sino Biopharm a reçu l'approbation de sa demande d’IND par la NMPA pour démarrer le développement clinique de lanifibranor en Chine
Regulatory Filings
2023-05-25 French
DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 25 MAI 2023
AGM Information
2023-05-25 French
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023
AGM Information
2023-05-25 English
Inventiva publie ses informations financières du 1er trimestre 2023¹ et fait un point sur ses activités
Earnings Release Q1 2023
2023-05-16 French
Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update
Earnings Release Q1 2023
2023-05-16 English
Information relative au nombre total de droits de vote et d’actions composant le capital social au 17 avril 2023
Declaration of Voting Results & Voting Rights Announcements
2023-05-04 French
Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-05-04 English
Assemblée Générale Mixte du 25 mai 2023. Modalités de mise à disposition des documents préparatoires
AGM Information
2023-05-04 French
Combined General Meeting of May 25, 2023. Availability of the preparatory documents
Report Publication Announcement
2023-05-04 English
Inventiva annonce le dépôt de son Document d'Enregistrement Universel 2022 et de son Rapport Annuel 2022 (« Form 20-F »)
Report Publication Announcement
2023-03-30 French
Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F
Report Publication Announcement FY 2022
2023-03-30 English
DEU 2022
Annual Report (ESEF) FY 2022
2023-03-29 French
DEU 2022
Annual Report (ESEF) FY 2022
2023-03-29 French
Inventiva publie ses résultats annuels 2022
Earnings Release FY 2022
2023-03-29 French
Document d'enregistrement universel 2022
Annual Report (ESEF) FY 2022
2023-03-29 French
Inventiva reports its 2022 full-year results
Earnings Release FY 2022
2023-03-29 English
Document d'enregistrement universel 2022
Annual Report (ESEF) FY 2023
2023-03-29 French
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results
Earnings Release FY 2022
2023-03-23 English
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2022
Report Publication Announcement
2023-03-23 French
Correction: Inventiva publie ses résultats financiers préliminaires pour l’exercice 2022¹
Earnings Release FY 2022
2023-02-14 French
Correction: Inventiva reports preliminary financial results for Full-Year 2022¹
Earnings Release FY 2022
2023-02-14 English
Inventiva publie ses résultats financiers préliminaires pour l’exercice 2022¹
Earnings Release FY 2022
2023-02-14 French
Inventiva reports preliminary financial results for Full-Year 2022¹
Earnings Release FY 2022
2023-02-14 English
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
Report Publication Announcement
2023-01-30 French
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Capital/Financing Update
2023-01-30 English
Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunie le 25 janvier 2023
Declaration of Voting Results & Voting Rights Announcements
2023-01-26 French
Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023
Declaration of Voting Results & Voting Rights Announcements
2023-01-26 English
Inventiva annonce des changements au développement clinique de lanifibranor notamment la préparation d’une nouvelle étude de Phase III chez les patients atteints de NASH avec une cirrhose compensée
Regulatory Filings
2023-01-04 French
Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis
Management Reports
2023-01-04 English
Information relative au nombre total de droits de vote et d’actions composant le capital social au 19 décembre 2022
Declaration of Voting Results & Voting Rights Announcements
2023-01-03 French
Statement of total voting rights and shares forming the company’s share capital as of December 19, 2022
Declaration of Voting Results & Voting Rights Announcements
2023-01-03 English
Combined General Meeting of January 25, 2023 - Availability of the preparatory documents
AGM Information
2023-01-03 English
Assemblée Générale Mixte du 25 janvier 2023 - Modalités de mise à disposition des documents préparatoires
AGM Information
2023-01-03 French